公开(公告)号：US11320439B2

公开(公告)日：2022-05-03

申请号：US16048028

申请日：2018-07-27

申请人： Siemens Healthcare Diagnostics Products GmbH

发明人： Harald Althaus ,  Herbert Schwarz ,  Norbert Zander

IPC分类号： G01N33/564 ,  G01N33/566 ,  G01N33/68 ,  G01N33/543

摘要： The present disclosure is in the field of in vitro diagnostics and relates to an easily automatable binding assay for establishing a heparin-induced thrombocytopenia, which binding assay uses FcγRIIa protein-coated particles.

公开(公告)号：US11241488B2

公开(公告)日：2022-02-08

申请号：US16611793

申请日：2018-05-10

申请人： New York University

发明人： Gregg Silverman

IPC分类号： A61K39/02 ,  A61P37/00 ,  A61P31/04 ,  A61K31/43 ,  A61K31/4706 ,  A61K31/573 ,  A61K35/741 ,  A61K38/17 ,  A61K39/395 ,  C12Q1/689 ,  G01N33/564

摘要： The application relates to methods for the diagnosis, treatment, and prevention of autoimmune and/or inflammatory disease such as systemic lupus erythematosus (SLE), lupus nephritis, IgA nephropathy, other types of glomerulonephritis.

公开(公告)号：US11236391B2

公开(公告)日：2022-02-01

申请号：US15662079

申请日：2017-07-27

申请人： Genentech, Inc.

发明人： Michael Townsend ,  Alvernia Francesca Setiadi ,  Tracy Staton

IPC分类号： A61K39/395 ,  C07K16/24 ,  C07K16/28 ,  C12Q1/6883 ,  G01N33/564 ,  A61K39/00

摘要： The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

公开(公告)号：US20210396751A1

公开(公告)日：2021-12-23

申请号：US17411724

申请日：2021-08-25

申请人： Progentec Diagnostics, Inc. ,  Oklahoma Medical Research Foundation

发明人： Melissa MUNROE ,  Judith JAMES ,  Eldon JUPE ,  Mohan PURUSHOTHAMAN

IPC分类号： G01N33/564 ,  G01N33/68

摘要： A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine/adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

公开(公告)号：US11204323B2

公开(公告)日：2021-12-21

申请号：US15681647

申请日：2017-08-21

申请人： Hycor Biomedical, LLC

发明人： Ronald Norman Diamond ,  Steven Michael Gann ,  Eric Darnell Hall ,  Tae Ho Hwang ,  John Lewis Morton ,  Anatoly Moskalev ,  Bruce Alan Sargeant ,  Dennis Edwin Rieger ,  Marinela Gombosev ,  Mark David Van Cleve

IPC分类号： G01N33/564 ,  G01N21/64 ,  G01N21/76 ,  G01N33/53 ,  G01N33/543 ,  G01N33/569 ,  G01N33/58 ,  G01N33/68 ,  G01N35/00 ,  G01N35/10 ,  G01N35/04

摘要： Apparatuses and methods of optically analyzing fluid within a pipette are described herein. In an embodiment, an optical reader subassembly includes a pipette configured to aspirate and hold a fluid sample within its tip, a housing configured to receive at least the tip of the pipette through a reentrant seal so that the tip of the pipette is located in a light tight manner within an internal area, a light source positioned to be in proximity to the tip of the pipette when the tip of the pipette is received by the housing, the light source configured to project light through the tip of the pipette and onto the fluid sample held within the tip, and an optical sensor configured to take a reading of the fluid sample held within the tip of the pipette without any of the fluid sample being injected from the pipette.

公开(公告)号：US20210389310A1

公开(公告)日：2021-12-16

申请号：US17216273

申请日：2021-03-29

申请人： ANNEXIN PHARMACEUTICALS AB

发明人： Johan FROSTEGÅRD

IPC分类号： G01N33/53 ,  A61K38/17 ,  C07K16/18 ,  G01N33/564 ,  G01N33/92 ,  C07K16/44

摘要： Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardivacular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.

公开(公告)号：US20210386829A1

公开(公告)日：2021-12-16

申请号：US17052873

申请日：2019-05-06

申请人： The Broad Institute, Inc. ,  Massachusetts Institute of Technology ,  The Brigham and Women's Hospital, Inc.

发明人： Antonia Wallrapp ,  Patrick R. Burkett ,  Vijay K. Kuchroo ,  Aviv Regev ,  Samantha J. Riesenfeld ,  Heping Xu

IPC分类号： A61K38/22 ,  G01N33/564 ,  A61K45/06 ,  A61P37/00

摘要： The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with homeostatic ILC2s and proinflammatory ILC2s that drive tissue inflammation. Molecular cues were identified that modulate ILC responses to alarmins using single-cell RNA-sequencing (scRNA-seq) profiles of lung-resident ILCs at steady state and after in vivo stimulation. The neuropeptide CGRP and the CGRP receptor were identified as expressed on ILC2s. Treatment with CGRP reduces allergic lung inflammation and reduces the proliferation and expansion of ILC2 cells. The results demonstrate that CGRP signaling strongly modulates ILC2 responses and highlights the importance of neuro-immune crosstalk in allergic inflammatory responses at mucosal surfaces.

公开(公告)号：US20210382049A1

公开(公告)日：2021-12-09

申请号：US17055835

申请日：2019-05-15

申请人： Navolab Diagnosztika Kft.

发明人： Gergely TOLDI ,  Kata FILKOR ,  Péter SZERÉMY ,  András APJOK ,  Zoltán SZEKANECZ

IPC分类号： G01N33/564 ,  G01N33/50 ,  G01N21/64

摘要： The relates to the field of diagnosis and treatment of Rheumatoid Arthritis, in particular of assessing responsiveness of rheumatoid arthritis patients to biological treatment. In particular the it has been found that measurement of MDR1 and/or MRP1 transport activities in the early phase of or before a bDMARD treatment is appropriate to provide a prediction on the effectiveness or success of bDMARD therapy once csDMARD therapy has failed. Thus, the invention relates to an in vitro diagnostic method for assessing the responsiveness of a sDMARD treated RA patient to bDMARD therapy, wherein preferably the patient is in need of a switch or modification of the sDMARD therapy by measuring transport activities of the above-mention transporters or their composite activities. The invention also relates to use of kits for the methods of the invention and methods for treatment comprising the diagnosis or prediction of the invention.

公开(公告)号：US11187708B2

公开(公告)日：2021-11-30

申请号：US16596258

申请日：2019-10-08

申请人： ROWAN UNIVERSITY

发明人： Robert G. Nagele

IPC分类号： G01N33/68 ,  G01N33/564

摘要： The present invention relates to diagnostic methods, reagents, and kits for detecting and diagnosing Early Stage Parkinson's disease.

公开(公告)号：US11175289B2

公开(公告)日：2021-11-16

申请号：US15352607

申请日：2016-11-16

申请人： Lei Han ,  Xiaohui Zhou ,  Yuyan Zhou ,  Li Zhou ,  Guohua Li ,  Yongzhen Li

发明人： Lei Han ,  Xiaohui Zhou ,  Yuyan Zhou ,  Li Zhou ,  Guohua Li ,  Yongzhen Li

IPC分类号： C07K14/705 ,  G01N33/564 ,  C07K16/28

摘要： A TRPM8 related peptide fragment, comprising amino acid sequence as shown in SEQ ID No: 1-18 is provided. Furthermore, application of TRPM8 protein, TRPM8 related peptide fragment and their antibodies in preparing diagnostic reagent for chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is provided. By detecting level of TRPM8 protein molecule, TRPM8 related peptide fragment and their antibodies, the chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is effectively diagnosed, and the present invention is capable of effectively making a distinction between CP/CPPS and other diseases of prostate. In addition, by intravenously or subcutaneously injecting 1˜30000 IU TRPM8 protein or TRPM8 related polypeptide fragments with or without combining nanoparticles for desensitization therapy, or monoclonal or polyclonal antibodies of the TRPM8 protein or polypeptide fragments, the present invention is capable of curing or significantly relieve clinical symptoms of the chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) and having an therapeutic effect.